ABSTRACT: Brain slices from 7-d-old Wistar rats were exposed to oxygen-glucose deprivation (OGD) for 30 min. OGD slices were incubated with vehicle or with the CB1/CB2 cannabinoid agonist WIN55212 (50 M), the CB1 agonist arachidonyl-2-chloroethylamide (ACEA) (50 M), or the CB2 agonist JW133 (50 M), alone or combined with the CB1 and CB2 receptor antagonist SR 141716 (50 M) or SR 144528 (50 M), respectively. Neuronal damage was assessed by histologic analysis and spectrophotometric determination of lactate dehydrogenase (LDH) efflux into the incubation medium. Additionally, medium glutamate levels were determined by highperformance liquid chromatography (HPLC) and those of tumor necrosis factor ␣ (TNF-␣) by enzyme-linked immunosorbent assay. Finally, inducible nitric oxide synthase (iNOS) and CB1/CB2 receptor expression were determined in slices homogenate by Western blot. Both CB1 and CB2 receptors were expressed in slices. OGD increased CB1 expression, cellular damage, LDH efflux, glutamate and TNF-␣ release, and inducible nitric oxide synthase (iNOS) expression; WIN55212 inhibited all these actions. SR141716 and SR144528 inhibited the effect of R(ϩ)-WIN-55212-2 (WIN), as well as the reduction of LDH efflux by ACEA and JW133, respectively. In conclusion, WIN55212 afforded robust neuroprotection in the forebrain slices exposed to OGD, by acting on glutamatergic excitotoxicity, TNF-␣ release, and iNOS expression; this neuroprotective effect seemed to be mediated by CB1 and CB2 receptors. P erinatal hypoxia-ischemia remains the single most important cause of brain injury in the newborn, leading to death or lifelong sequelae (1,2). The complexities of neonatal hypoxic-ischemic encephalopathy (NHIE) pathophysiology suggest that successful neuroprotection could be achieved only with a multitherapeutic approach (2). In recent years, interest in the neuroprotective possibilities of cannabinoids has grown (3-5). Endocannabinoids emerge as natural brain protective substances in different damaging situations (3,4); in newborn rats, enhanced levels of cannabinoids have been observed in the brain after acute excitotoxic insult (6). Exogenous cannabinoid agonists are neuroprotective in different paradigms of brain injury (7,8); they inhibit intracellular calcium influx, reduce glutamate and TNF-␣ release, decrease stimulated iNOS expression, induce hypothermia, and exert immunomodulatory and antioxidant actions (3-5,9,10). Some of these effects are dependent on the activation of the principal brain cannabinoid receptors, the CB1 receptors, and others are dependent on the molecular properties of the cannabinoid or the activation of non-CB1 receptors (3). There are few studies regarding the possible neuroprotective effect of cannabinoids in newborns. Early studies describe that the administration of anandamide (11) or the cannabinoid agonist ⌬ (9)-tetrahydrocannabinol (12) affords neuroprotection in a newborn rat model with excitotoxic neuronal injury. It has also been demonstrated that the cannabinoid agonist WIN, prevents early neuronal death by CB1-independent mechanisms, and prevents late neuronal death by CB1-dependent mechanisms in a model of acute asphyxia in newborn rats (13).
P erinatal hypoxia-ischemia remains the single most important cause of brain injury in the newborn, leading to death or lifelong sequelae (1, 2) . The complexities of neonatal hypoxic-ischemic encephalopathy (NHIE) pathophysiology suggest that successful neuroprotection could be achieved only with a multitherapeutic approach (2) . In recent years, interest in the neuroprotective possibilities of cannabinoids has grown (3) (4) (5) . Endocannabinoids emerge as natural brain protective substances in different damaging situations (3, 4) ; in newborn rats, enhanced levels of cannabinoids have been observed in the brain after acute excitotoxic insult (6) . Exogenous cannabinoid agonists are neuroprotective in different paradigms of brain injury (7, 8) ; they inhibit intracellular calcium influx, reduce glutamate and TNF-␣ release, decrease stimulated iNOS expression, induce hypothermia, and exert immunomodulatory and antioxidant actions (3) (4) (5) 9, 10) . Some of these effects are dependent on the activation of the principal brain cannabinoid receptors, the CB1 receptors, and others are dependent on the molecular properties of the cannabinoid or the activation of non-CB1 receptors (3) . There are few studies regarding the possible neuroprotective effect of cannabinoids in newborns. Early studies describe that the administration of anandamide (11) or the cannabinoid agonist ⌬ (9)-tetrahydrocannabinol (12) affords neuroprotection in a newborn rat model with excitotoxic neuronal injury. It has also been demonstrated that the cannabinoid agonist WIN, prevents early neuronal death by CB1-independent mechanisms, and prevents late neuronal death by CB1-dependent mechanisms in a model of acute asphyxia in newborn rats (13) .
In our study, we investigated the mechanisms involved in the prevention of early hypoxic-ischemic neuronal death in the newborn rat brain using WIN. This involved an in vitro model using the exposure of newborn rat brain slices to OGD. This reproduces most the mechanisms of hypoxic-ischemic damage in the newborn brain, as glutamatergic excitotoxicity, cytokine release, or NO toxicity, with characteristics different from those of adult rat brain slice OGD; it is therefore considered an in vitro model of NHIE (14) .
METHODS
Preparation and incubation of slices. The experimental protocol has been described elsewhere (14) . Briefly, newborn Wistar rats (7-10 d old) were killed by decapitation (according to the Committee of Animal Care at the Universidad Complutense of Madrid), the forebrain was removed and coronally cut (1 mm anterior and 3 mm posterior to the bregma), and the central portion was sliced (0.5 mm slice thickness) using a Vibroslice (WPI, Stevenage, UK) into cold (12-14°C) modified Krebs-Henseleit solution (preincubation solution) containing (mM): NaCl (120), KCl (2), CaCl2 (0.5), NaHCO3 (26), MgSO4 (10), KH2PO4 (1.18), glucose (11), and sucrose (200). Slices were incubated in sucrose-free preincubation solution for 45 min and later in a modified Krebs-Henseleit solution (incubation solution) containing (mM): NaCl (120), KCl (2), CaCl2 (2), NaHCO3 (26), MgSO4 (1.19), KH2PO4 (1.18), glucose (11) and 5,6,7,8-tetrahydrobiopterin (BH4, 10 mM), bubbled with 95% O 2 /5% CO 2 in a shaking water bath at 37°C.
The slices of the control group (CG, n ϭ 28) were then incubated 30 min further in the same conditions, and slices of the "ischemic" experimental group (OGD, n ϭ 30) were incubated for 30 min in incubation solution without glucose and equilibrated with 95% N 2 /5% CO 2 . In all groups, the end of the period of 30 min was considered as time 0 (t0). After these periods of 30 min, the medium was replaced with fresh incubation solution equilibrated with 95% O 2 /5% CO 2 ("reperfusion" phase). Thereafter, the incubation solution was renewed every 30 min, up to and including 150 min (t150). Samples were taken each time the incubation solution was replaced, except the sample to determine TNF-␣ levels, which was collected once only at t150. At t150, slices were taken out and frozen immediately with liquid nitrogen.
Before starting to study the neuroprotective effect of WIN, tests were run using a concentration of WIN from 0.5 to 100 M, to obtain the optimal drug concentration. Next, at this optimal concentration, WIN alone (WIN, n ϭ 14), or with the CB1 receptor antagonist SR141716 (50 M; SR1, n ϭ 7), or the CB2 receptor antagonist SR144528 (50 M, n ϭ 8) was added to the preincubation solution, remaining present until the end of the experiment. In another set of experiments, the CB1-specific agonist arachidonyl-2-chloroethylamide (ACEA) (50 M, n ϭ 10), alone or with SR1 (50 M, n ϭ 8), or the CB2-specific agonist 1,1-dimethylbutyl-1-deoxy-⌬ (9)-tetrahydrocannabinol (JWH133) (50 M; JW, n ϭ 10), alone or with SR2 (50 M, n ϭ 8) was added.
Histologic study. At the end of the experiment, the brain slices were fixed overnight in 4% paraformaldehyde. They were then embedded in paraffin and cut into 3-m sections using a microtome. Each section was stained using Nissl's technique and observed with a Nikon Eclipse 90i microscope with a Nikon Digital Camera DXM 1200F, coupled to computerized imageprocessing software (Metamorph 6.3r1, Molecular Devices Corp.). Digital microphotographs (ϫ400) were taken from three different 500-m 2 areas of striatum using slices from at least three different specimens to count viable neurons with their nuclei present in the focal plane. Cell counting was performed by an investigator blinded to the experimental protocol.
LDH activity assay. As a marker of necrotic tissue damage, LDH released from damaged cells in the slices was determined in the incubation solution, as previously described (14) . LDH activity was measured spectrophotometrically at 340 nm by following the oxidation of NADH (decrease in absorbance) in the presence of pyruvate using a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA). LDH efflux was expressed as the LDH activity present in the incubation solution. Data are expressed as mOD/min and reflect the total LDH release.
HPLC determination of glutamate concentration. Samples of the incubation solution were collected at t0. Analysis of glutamate in each sample was performed by HPLC with fluorimetric detection (Perkin Elmer Binary LC Pump 250 and Fluorescence Detector LC 240) following precolumn derivatization with the o-phtalaldialdehyde procedure, as previously described (14) . Glutamate derivatives were separated isocratically on a reverse phase column (4.6 ϫ 150 mm, 5-mm particle diameter, Nucleosil 100-C18) using a mobile phase consisting of sodium acetate buffer (0.05 M, pH 6.5), 20% methanol and 2% tetrahydrofuran. The area of each peak was determined with a Perkin Elmer Nelson Model 1020 integrator (Phoenix 8088 ROM BIOS Version 2.52 software) and compared with the peak area of the corresponding external standard. The limit of detection in these conditions was 10 ng/mL.
Western blot analyses. For analysis of iNOS, CB1, and CB2 expression, slices were homogenized in lysis buffer (10 mM Tris, pH 8.0; 0.2% Nonidet P-40;1 mM dithioerythritol); after centrifugation for 15 min, the proteins present in the supernatant were loaded (10 g) and size-separated in 10% SDS-polyacrylamide gel electrophoresis (50 mA), as previously described (14) . The gels were blotted onto a PVDF membrane (Millipore, Bedford, MA), incubated with specific polyclonal antibodies against iNOS (Santa Cruz Biotechnology, Santa Cruz, CA; 1:1000 dilution), CB1 and CB2 (Chemicon International Inc; both at a 1:300 dilution), and processed as recommended by the supplier. Proteins recognized by the antibodies were revealed by an ECL kit following the manufacturer's instructions (Amersham Iberica, Madrid, Spain). INOS, CB1, and CB2 expression was quantified by densitometric analysis of bands. Commercial markers (Bio-Rad prestained) were used as molecular weight standards, and ␤-actin was used to normalize the protein lane charge of the blot.
TNF-␣ determination. Soluble TNF-␣ released from cells into the incubation solution was determined by a rat TNF-␣ immunoassay (Rat TNF-␣ UltraSensitive, Biosource International Inc., Camarillo, CA.
Chemicals and statistical analyses. SR141716 and SR144528 were a generous gift from Sanofi-Synthelabo (Paris, France). BH4 was obtained from RBI, and, unless otherwise stated, the other chemicals were from Sigma Chemical Co. (Madrid, Spain).
Results are expressed as mean Ϯ SEM of the indicated number of experiments. Statistical comparisons were made using analysis of variance (ANOVA), with the Newman-Keuls test for multiple comparisons. A p value Ͻ0.05 was considered as statistically significant. Statistical analysis was performed using the 11.0.0 version of SPSS software (SPSS Inc.).
RESULTS

Expression of the cannabinoid receptors CB1 and CB2.
Western blot analysis at t150 demonstrated the presence of the CB1 and CB2 receptors in the CG. OGD induced a significant increase in CB1 expression but not an increase in CB2 expression (Fig. 1) .
Characterization of the effect of WIN on brain injury after OGD. As observed after Nissl staining, OGD led to severe tissue damage, with a large reduction in the number of viable neurons (Fig. 2) . Viable striatal neuron density was 348.4 Ϯ 14.6 versus. 33.3 Ϯ 2.8 per mm 2 for CG and OGD, respectively. In CG, LDH efflux was minimal and remained stable throughout the 150-min experimental period; by contrast, OGD induced a significant increase in LDH efflux during the entire experimental period, as we have described previously (14) (Fig. 3) . Prior incubation of OGD slices with WIN reduced LDH efflux in a dose-dependent manner (Fig. 3) . A concentration of 50 M was the most effective dose, reducing LDH efflux to levels similar to those in CG (Fig. 3) . Higher concentration, however, further increased LDH efflux, suggesting some toxic effect (Fig. 3) . Thus, a concentration of 50 M was selected as the optimal WIN concentration for experiments. Based on its Ki values, similar concentration of ACEA and JW were selected after testing showed a higher concentration was not more effective.
In addition to reducing LDH efflux, WIN increased the number of viable neurons observed under the microscope (264.1 Ϯ 10.9 per mm 2 , p Ͻ 0.05 versus OGD) (Fig. 2) . Co-incubation with either SR1 or SR2 inhibited both protective effects of WIN (Figs. 2 and 4A) ; neuronal density was 50.1 Ϯ 2.3 and 59.5 Ϯ 3.1 per mm 2 for SR1 and SR2, respectively (p Ͻ 0.05 versus CG and WIN). Co-incubation of WIN with SR1 and SR2 together had no additional inhibiting effect (data not shown). Incubation with ACEA or JW reduced LDH efflux, but to a lesser extent than with WIN (Fig. 4B) . The effect was receptor specific, as SR1 reversed the effect of ACEA as did SR2 with JW (data not shown).
Effect of WIN on glutamate and TNF-␣ concentration and iNOS expression. OGD induced a significant increase in glutamate concentration in the incubation medium (Fig. 5A ). This increase was reduced by WIN to Ͻ50% of the OGD values (Fig. 5A) . Co-incubation with SR1 or SR2 eliminated the WIN-induced reduction of glutamate concentration.
When compared with CG, exposure to OGD caused a twofold increase in TNF-␣ concentration (Fig. 5B) . WIN inhibited this increase in TNF-␣, with concentrations lower than those found in CG. Co-incubation with SR1 or SR2 inhibited the TNF-␣ reduction by WIN.
In CG slice homogenate, a small expression of iNOS was detected by Western blot analysis (Fig. 6) . In contrast, OGD caused a strong overexpression of iNOS (Fig. 4) . This overexpression was attenuated by WIN (Fig. 6 ). This effect of WIN was counteracted by SR1 or SR2 co-incubation (Fig. 6 ).
DISCUSSION
We have demonstrated for the first time that (1) a cannabinoid agonist induced a robust neuroprotective effect in an in vitro model of NHIE; (2) this neuroprotective effect is related to the modulation of some relevant factors involved in hy- 
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poxic-ischemic brain damage; (3) CB2 receptors play a relevant role, offering interesting therapeutic options; and (4) the simultaneous activation of both CB1 and CB2 receptors offers more benefits than CB1 or CB2 activation alone.
The neuroprotective effects shown confirm those previously observed by us in an in vivo model of NHIE in rats (13) and offer cannabinoids as a promising strategy against acute neurodegeneration (3, 4, 7, 8) . The 50-M dose of WIN used is higher than that commonly used in cell cultures (7) due to the thickness of the forebrain slices (500 m). These required greater drug concentrations to achieve appropriate WIN concentration in the deepest layers of the slice. LDH efflux in brain slices incubated with 50 M of WIN remained stable throughout the experiment and at levels similar to those of the CG, supporting the neuroprotective effect of WIN and also its lack of toxic effects. Our experiments have analyzed for the first time the effects of a cannabinoid on the activation of some critical factors that determine neuronal death in NHIE. These factors include glutamatergic excitotoxicity, TNF-␣ release, and iNOS expression (1, 2) . The immature brain is selectively vulnerable to glutamatergic excitotoxicity (1,14 -16) . WIN reduced glutamate concentration in the incubation medium when compared with untreated OGD brain slices alone. Drugs reducing glutamate release are of particular value in neuroprotection in NHIE, as glutamate receptor blockers are neurotoxic in immature brains (2) . Cannabinoids are known to inhibit glutamate release by presynaptic G protein-coupled receptor activation (17) (18) (19) (20) (21) (22) .
WIN led to a decrease in TNF-␣ release. Great attention is paid to the role of TNF-␣ in NHIE because it is particularly harmful to the immature brain. It is involved in apoptotic and oxidative injury processes using different mechanisms, including iNOS induction (1, 14, 23, 24) . Cannabinoids inhibit the increase in TNF-␣ production after immunologic stimuli, both in vivo and in vitro (10) by modulating different transcriptional factors (25) and enhancing the release of the endogenous interleukin-1 receptor antagonist (IL-1ra) (26) . In addition to this, cannabinoids reduce the release of glutamate, which in turn enhances TNF-␣ release by activation of its secretase, TNF-␣ convertase (TACE/ADAM17) (27) . Interestingly, WIN reduced TNF-␣ concentrations to an even lower level than those of the CG, suggesting that some stimulation of TNF-␣ release derived from brain slice manipulation occurs, thus emphasizing the anti-inflammatory effect of cannabinoids (5, 10, 26) .
Expression of iNOS was increased by OGD, as reported (14, 28) . Different mechanisms participate in iNOS induction during hypoxia, including TNF-␣ (23) or glutamate (28) release; massive production of NO after induction of iNOS plays a major role in hypoxic brain injury (1, 16, 29) . The induction of iNOS after OGD was counteracted by WIN. Cannabinoids inhibit iNOS expression in glial cells after different stimuli (9, 26, 30) by enhancing IL-1ra release (26) and inhibiting the transcriptional activity of the nuclear factor-B (NF-B) (9, 31) . This effect on NF-B activity is of particular importance because this is the mechanism by which glutamate induces the expression of iNOS (28) .
Western blot revealed the presence of CB1 receptors in newborn rat brain slices and, for the first time, CB2 receptors. The neuroprotective effect of WIN was eliminated by SR1 and SR2, suggesting the participation of both CB1 and CB2 receptors in this effect. CB1 receptors are found in the brain during the early prenatal developmental stages, increasing in density soon after birth (32) . CB1 was overexpressed 150 min after OGD, as observed 2 h after focal ischemia in the rat brain (33) . This agrees with the suggested role of endocannabinoids as natural neuroprotectors after brain injuries (4, 6) . Our results suggesting the participation of CB1 receptors in WIN-induced neuroprotection are supported by LDH efflux reduction by ACEA and confirm previous results from ischemic brain injury experiments in mice (34) . SR1 reversed the WINinduced reduction of glutamate release. Although the role of CB1 in cannabinoid reduction of glutamate release in adult brain remains controversial (17) (18) (19) (20) (21) (22) , our results support a role for these receptors in cannabinoid prevention of excitotoxic damage in newborn brain, as reported (11,12). SR1 not only reversed the WIN-induced reduction of glutamate release, but increased OGD-induced glutamate release. Similar results were observed in cultured cerebellar neurons and have been interpreted as inverse agonism of SR1 or the block in activity of endogenous ligands at cannabinoid receptors (17) . We also confirmed the involvement of CB1 receptors in WIN modulation of TNF-␣ release and iNOS expression enhancement, an effect thought to be exerted on glial cells (9, 10) .
Recently, CB2 receptors have been discovered in brain neurons (35) and microglial cells (36) , both being present in the forebrain slices that we used. A striking result of our study was the elimination of WIN neuroprotection by SR2. JW, a selective CB2 agonist, was also equally capable of reducing LDH efflux. This is, to our knowledge, the first report of CB2 intermediation of cannabinoid neuroprotection in models of brain ischemia. CB2 receptors are overexpressed in glial cells in different paradigms of inflammatory brain insult (37, 38) ; although inflammation plays a pivotal role in ischemic brain damage (24), we did not observe an increase in CB2 expression in OGD brain slices. It has been reported that in cultured cells, CB2 receptors participate in the reduction by cannabinoids, of lipolysaccharide-induced TNF-␣ release (10) and iNOS expression increase (26, 30) ; ours is the first evidence of a CB2-mediated reduction of TNF-␣ release and iNOS expression in a model of hypoxic-ischemic brain damage. In addition, we have also described for the first time that CB2 participated in the reduction of glutamate release by WIN, involving them in the modulatory effect of cannabinoids on excitotoxic brain damage. Our results support the possibility of a cannabinoid-based therapeutic intervention, free from psychotropic effects, as CB2 receptors do not mediate the psychoactive effects of cannabinoids (39) .
Interestingly, the neuroprotective effect of WIN, a CB1/ CB2 agonist, was greater than that of selective CB1 or CB2 agonists. In fact, LDH efflux was similar in WINϩSR1 and JW, as well as in WINϩSR2 and ACEA. These data suggest that simultaneous activation of both CB1 and CB2 receptors was more effective in modulating the factors involved in hypoxic-ischemic brain damage than CB1 or CB2 alone. Studies on neuronal and glial cultures have shown that the neuroprotective action of cannabinoids in response to inflammatory or excitotoxic insults is mediated by both CB1 and CB2 receptor-dependent pathways (26) . Co-incubation of WIN with SR1 and SR2 did not increase the inhibitory effect of SR1 or SR2 alone, suggesting that WIN might also act on receptor(s) other than CB1 and CB2 (21) .
In conclusion, WIN showed a robust neuroprotective effect on 7-d-old rat forebrain slices exposed to OGD, based on the reduction of glutamate release, TNF-␣ release, and iNOS expression. The effect of WIN was mediated by both CB1 and CB2 receptors. Our results support a major role for cannabinoids in neuroprotective strategies, opening an exciting field of investigation in the role of CB2 receptors in NHIE pathophysiology and therapeutics.
